Recombinant Human PD-1 Fc Chimera Protein, CF | R&D Systems 1086-PD product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human PD-1 Fc Chimera Protein, CF

catalog :

1086-PD

quantity :

1 mg

price :

3200 USD

citations: 18

Reference
Liberelle M, Magnez R, Thuru X, Bencheikh Y, Ravez S, Quenon C, et al. MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis. Sci Rep. 2019;9:16678 pubmed publisher
Passariello M, D Alise A, Esposito A, Vetrei C, Froechlich G, Scarselli E, et al. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling. Sci Rep. 2019;9:13125 pubmed publisher
Wang W, Chapman N, Zhang B, Li M, Fan M, Laribee R, et al. Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation-Induced Immune Suppression. Cancer Res. 2019;79:2909-2922 pubmed publisher
Zhang N, Dou Y, Liu L, Zhang X, Liu X, Zeng Q, et al. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. EBioMedicine. 2019;40:151-162 pubmed publisher
Wang H, Yao H, Li C, Shi H, Lan J, Li Z, et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 2019;15:42-50 pubmed publisher
Shao B, Li C, Lim S, Sun L, Lai Y, Hou J, et al. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. Am J Cancer Res. 2018;8:1837-1846 pubmed
Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3: pubmed publisher
Li C, Lim S, Chung E, Kim Y, Park A, Yao J, et al. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018;33:187-201.e10 pubmed publisher
Chatterjee S, Lesniak W, Miller M, Lisok A, Sikorska E, Wharram B, et al. Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochem Biophys Res Commun. 2017;483:258-263 pubmed publisher
Li C, Lim S, Xia W, Lee H, Chan L, Kuo C, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632 pubmed publisher
Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature. 2016;534:402-6 pubmed publisher
Yang Y, Wu K, Zhao E, Li W, Shi L, Xie G, et al. B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor. Oncol Lett. 2015;9:1833-1838 pubmed
Melendreras S, MartÃnez Camblor P, MenÃ©ndez A, Bravo Mendoza C, GonzÃ¡lez Vidal A, Coto E, et al. Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS ONE. 2014;9:e113396 pubmed publisher
Steidl C, Shah S, Woolcock B, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377-81 pubmed publisher
Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-75 pubmed publisher
Kim Y, Park G, Lee H, Song H, Choi I, Lee W, et al. Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression. J Immunol. 2008;181:6158-69 pubmed
Sakthivel P, Ramanujam R, Wang X, Pirskanen R, Lefvert A. Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis. J Neuroimmunol. 2008;193:149-55 pubmed
Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177:8844-50 pubmed

product information

brand :

R&D Systems

master code :

1086-PD

SKU :

1086-PD-01M

product name :

Recombinant Human PD-1 Fc Chimera Protein, CF

description :

The Recombinant Human PD-1 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human PD-1 Fc Chimera Protein, CF has been validated for the following applications: Binding Activity.

target :

PD-1

category :

Proteins and Enzymes

unit size :

1 mg

buffer :

Lyophilized from a 0.2 µm filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

species :

Human

observed molecular weight :

60-70 kDa, reducing conditions

theoretical molecular weight :

42.6 kDa (monomer)

gene symbol :

PDCD1

details of functionality :

Measured by its binding ability in a functional ELISA. When Recombinant Human PD-1 Fc Chimera is immobilized at 0.1 µg/mL (100 µL/well), Recombinant Human B7-H1/PD-L1 Fc Chimera (Catalog # 156-B7 ) binds with a typical ED50 of 0.15-0.75 µg/mL.

endotoxin note :

<0.01 EU per 1 µg of the protein by the LAL method.

catalog number base :

1086-PD

accessionNumbers :

Q15116

applications :

Binding Activity

source :

Mouse myeloma cell line, NS0-derived human PD-1 protein Human PD-1 (Leu25-Gln167) Accession # Q15116 IEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus

2020 USD :

3200

2021 USD :

3200 USD

alt names :

CD279, CD279 antigen, hPD-1, PD1, PD1hPD-l, PDCD1, programmed cell death 1, programmed cell death protein 1, Protein PD-1, SLEB2

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.